Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of vorinostat when given
together with trastuzumab and to see how well they work in treating patients with metastatic
breast canceror breast cancer that has recurred in the chest wall. Vorinostat may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal
antibodies, such as trastuzumab, can block tumor growth in different ways. Some find tumor
cells and kill them or carry tumor-killing substances to them. Others interfere with the
ability of tumor cells to grow and spread. Vorinostat and trastuzumab also may stop the
growth of tumor cells by blocking blood flow to the tumor. Giving vorinostat together with
trastuzumab may be a better way to block tumor growth.